Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86

1.

Stromal coexpression of uPA/PAI-1 protein predicts poor disease outcome in endocrine-treated postmenopausal patients with receptor-positive early breast cancer.

Singer CF, Filipits M, Jahn SW, Abete L, Jakesz R, Greil R, Bauernhofer T, Kwasny W, Seifert M, Fitzal F, Kastner M, Schmitt M, Moinfar F, Gnant M.

Breast. 2019 Aug;46:101-107. doi: 10.1016/j.breast.2019.05.007. Epub 2019 May 3.

PMID:
31132475
2.

Impact of Breast Surgery in Primary Metastasized Breast Cancer: Outcomes of the Prospective Randomized Phase III ABCSG-28 POSYTIVE Trial.

Fitzal F, Bjelic-Radisic V, Knauer M, Steger G, Hubalek M, Balic M, Singer C, Bartsch R, Schrenk P, Soelkner L, Greil R, Gnant M; ABCSG.

Ann Surg. 2019 Jun;269(6):1163-1169. doi: 10.1097/SLA.0000000000002771.

PMID:
31082916
3.

Prediction of Distant Recurrence Using EndoPredict Among Women with ER+, HER2- Node-Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only.

Filipits M, Dubsky P, Rudas M, Greil R, Balic M, Bago-Horvath Z, Singer CF, Hlauschek D, Brown K, Bernhisel R, Kronenwett R, Lancaster JM, Fitzal F, Gnant M.

Clin Cancer Res. 2019 Jul 1;25(13):3865-3872. doi: 10.1158/1078-0432.CCR-19-0376. Epub 2019 May 7.

PMID:
31064782
4.

Is breast implant-associated anaplastic large cell lymphoma a hazard of breast implant surgery?

Fitzal F, Turner SD, Kenner L.

Open Biol. 2019 Apr 26;9(4):190006. doi: 10.1098/rsob.190006.

5.

Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial.

Gnant M, Pfeiler G, Steger GG, Egle D, Greil R, Fitzal F, Wette V, Balic M, Haslbauer F, Melbinger-Zeinitzer E, Bjelic-Radisic V, Jakesz R, Marth C, Sevelda P, Mlineritsch B, Exner R, Fesl C, Frantal S, Singer CF; Austrian Breast and Colorectal Cancer Study Group.

Lancet Oncol. 2019 Mar;20(3):339-351. doi: 10.1016/S1470-2045(18)30862-3. Epub 2019 Feb 19.

PMID:
30795951
6.

Continued Endocrine Therapy Is Associated with Improved Survival in Patients with Breast Cancer Brain Metastases.

Bergen ES, Berghoff AS, Medjedovic M, Rudas M, Fitzal F, Bago-Horvath Z, Dieckmann K, Mader RM, Exner R, Gnant M, Zielinski CC, Steger GG, Preusser M, Bartsch R.

Clin Cancer Res. 2019 May 1;25(9):2737-2744. doi: 10.1158/1078-0432.CCR-18-1968. Epub 2019 Jan 15.

PMID:
30647078
7.

Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS): study protocol for a multicenter, randomized phase-III trial.

Henke G, Knauer M, Ribi K, Hayoz S, Gérard MA, Ruhstaller T, Zwahlen DR, Muenst S, Ackerknecht M, Hawle H, Fitzal F, Gnant M, Mátrai Z, Ballardini B, Gyr A, Kurzeder C, Weber WP.

Trials. 2018 Dec 4;19(1):667. doi: 10.1186/s13063-018-3021-9.

8.

The influence of breast cancer subtypes on axillary ultrasound accuracy: A retrospective single center analysis of 583 women.

Helfgott R, Mittlböck M, Miesbauer M, Moinfar F, Haim S, Mascherbauer M, Schlagnitweit P, Heck D, Knauer M, Fitzal F.

Eur J Surg Oncol. 2019 Apr;45(4):538-543. doi: 10.1016/j.ejso.2018.10.001. Epub 2018 Oct 10.

PMID:
30366878
9.

Post SABCS local therapy and radiology.

Fitzal F.

Memo. 2018;11(3):213-216. doi: 10.1007/s12254-018-0403-3. Epub 2018 May 15. Review.

10.

Oncoplastic Breast Consortium consensus conference on nipple-sparing mastectomy.

Weber WP, Haug M, Kurzeder C, Bjelic-Radisic V, Koller R, Reitsamer R, Fitzal F, Biazus J, Brenelli F, Urban C, Paulinelli RR, Blohmer JU, Heil J, Hoffmann J, Matrai Z, Catanuto G, Galimberti V, Gentilini O, Barry M, Hadar T, Allweis TM, Olsha O, Cardoso MJ, Gouveia PF, Rubio IT, de Boniface J, Svensjö T, Bucher S, Dubsky P, Farhadi J, Fehr MK, Fulco I, Ganz-Blättler U, Günthert A, Harder Y, Hauser N, Kappos EA, Knauer M, Landin J, Mechera R, Meani F, Montagna G, Ritter M, Saccilotto R, Schwab FD, Steffens D, Tausch C, Zeindler J, Soysal SD, Lohsiriwat V, Kovacs T, Tansley A, Wyld L, Romics L, El-Tamer M, Pusic AL, Sacchini V, Gnant M.

Breast Cancer Res Treat. 2018 Dec;172(3):523-537. doi: 10.1007/s10549-018-4937-1. Epub 2018 Sep 4. Review.

11.

Risk factors for locoregional disease recurrence after breast-conserving therapy in patients with breast cancer treated with neoadjuvant chemotherapy: An international collaboration and individual patient meta-analysis.

Valachis A, Mamounas EP, Mittendorf EA, Hayashi N, Ishitobi M, Natoli C, Fitzal F, Rubio IT, Tiezzi DG, Shin HC, Anderson SJ, Hunt KK, Matsuda N, Ohsumi S, Totomi A, Nilsson C.

Cancer. 2018 Jul 15;124(14):2923-2930. doi: 10.1002/cncr.31518. Epub 2018 May 3.

12.

Impact of Breast Surgery in Primary Metastasized Breast Cancer: Outcomes of the Prospective Randomized Phase III ABCSG-28 POSYTIVE Trial.

Fitzal F, Bjelic-Radisic V, Knauer M, Steger G, Hubalek M, Balic M, Singer C, Bartsch R, Schrenk P, Soelkner L, Greil R, Gnant M; ABCSG.

Ann Surg. 2018 Apr 24. doi: 10.1097/SLA.0000000000002771. [Epub ahead of print]

PMID:
29697452
13.

Adjuvant Bisphosphonate Therapy in Postmenopausal Breast Cancer.

Strobl S, Wimmer K, Exner R, Devyatko Y, Bolliger M, Fitzal F, Gnant M.

Curr Treat Options Oncol. 2018 Mar 12;19(4):18. doi: 10.1007/s11864-018-0535-z. Review.

PMID:
29527635
14.

Optimal duration of adjuvant endocrine therapy: how to apply the newest data.

Wimmer K, Strobl S, Bolliger M, Devyatko Y, Korkmaz B, Exner R, Fitzal F, Gnant M.

Ther Adv Med Oncol. 2017 Nov;9(11):679-692. doi: 10.1177/1758834017732966. Epub 2017 Oct 27. Review.

15.

Sized Influences Nodal Status in Women Aged #70 with Endocrine Responsive Breast Cancer.

Fitzal F, Helfgott R, Moinfar F, Gnant M.

Ann Surg Oncol. 2017 Dec;24(Suppl 3):555-556. doi: 10.1245/s10434-017-6156-0. Epub 2017 Nov 20. No abstract available.

PMID:
29159741
16.

First international consensus conference on standardization of oncoplastic breast conserving surgery.

Weber WP, Soysal SD, El-Tamer M, Sacchini V, Knauer M, Tausch C, Hauser N, Günthert A, Harder Y, Kappos EA, Schwab F, Fitzal F, Dubsky P, Bjelic-Radisic V, Reitsamer R, Koller R, Heil J, Hahn M, Blohmer JU, Hoffmann J, Solbach C, Heitmann C, Gerber B, Haug M, Kurzeder C.

Breast Cancer Res Treat. 2017 Aug;165(1):139-149. doi: 10.1007/s10549-017-4314-5. Epub 2017 Jun 3.

PMID:
28578506
17.

Objective breast symmetry analysis with the breast analyzing tool (BAT): improved tool for clinical trials.

Krois W, Romar AK, Wild T, Dubsky P, Exner R, Panhofer P, Jakesz R, Gnant M, Fitzal F.

Breast Cancer Res Treat. 2017 Jul;164(2):421-427. doi: 10.1007/s10549-017-4255-z. Epub 2017 May 2.

18.

Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast Cancer.

Singer CF, Tan YY, Fitzal F, Steger GG, Egle D, Reiner A, Rudas M, Moinfar F, Gruber C, Petru E, Bartsch R, Tendl KA, Fuchs D, Seifert M, Exner R, Balic M, Bago-Horvath Z, Filipits M, Gnant M; Austrian Breast and Colorectal Cancer Study Group.

Clin Cancer Res. 2017 Jul 15;23(14):3676-3683. doi: 10.1158/1078-0432.CCR-16-2373. Epub 2017 Jan 31.

19.

Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial.

Gnant M, Pfeiler G, Dubsky PC, Hubalek M, Greil R, Jakesz R, Wette V, Balic M, Haslbauer F, Melbinger E, Bjelic-Radisic V, Artner-Matuschek S, Fitzal F, Marth C, Sevelda P, Mlineritsch B, Steger GG, Manfreda D, Exner R, Egle D, Bergh J, Kainberger F, Talbot S, Warner D, Fesl C, Singer CF; Austrian Breast and Colorectal Cancer Study Group.

Lancet. 2015 Aug 1;386(9992):433-43. doi: 10.1016/S0140-6736(15)60995-3. Epub 2015 May 31.

PMID:
26040499
20.

The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial.

Fitzal F, Filipits M, Rudas M, Greil R, Dietze O, Samonigg H, Lax S, Herz W, Dubsky P, Bartsch R, Kronenwett R, Gnant M.

Br J Cancer. 2015 Apr 14;112(8):1405-10. doi: 10.1038/bjc.2015.98. Epub 2015 Mar 24.

21.

Taxanes Plus Trastuzumab Compared To Oral Vinorelbine Plus Trastuzumab in HER2-Overexpressing Metastatic Breast Cancer.

Bergen E, Berghoff AS, Rudas M, Dubsky P, De Vries C, Sattlberger C, Mader RM, Zagouri F, Sparber C, Fitzal F, Gnant M, Rottenfusser A, Zielinski CC, Preusser M, Steger GG, Bartsch R.

Breast Care (Basel). 2014 Oct;9(5):344-8. doi: 10.1159/000368330. Erratum in: Breast Care (Basel). 2016 Feb;11(1):20.

22.

Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12.

Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Knauer M, Moik M, Jakesz R, Seifert M, Taucher S, Bjelic-Radisic V, Balic M, Eidtmann H, Eiermann W, Steger G, Kwasny W, Dubsky P, Selim U, Fitzal F, Hochreiner G, Wette V, Sevelda P, Ploner F, Bartsch R, Fesl C, Greil R; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria.

Ann Oncol. 2015 Feb;26(2):313-20. doi: 10.1093/annonc/mdu544. Epub 2014 Nov 17.

PMID:
25403582
23.

Lymph node staging in invasive breast cancer.

Fitzal F, Galimberti V, Kühn T, Rutgers EJ, Untch M.

Breast Care (Basel). 2014 Jul;9(3):211-4. doi: 10.1159/000365315. No abstract available.

24.

Co-overexpression of HER2/HER3 is a predictor of impaired survival in breast cancer patients.

Berghoff AS, Bartsch R, Preusser M, Ricken G, Steger GG, Bago-Horvath Z, Rudas M, Streubel B, Dubsky P, Gnant M, Fitzal F, Zielinski CC, Birner P.

Breast. 2014 Oct;23(5):637-43. doi: 10.1016/j.breast.2014.06.011. Epub 2014 Jul 10.

PMID:
25017122
25.

The multigene signature MammaPrint impacts on multidisciplinary team decisions in ER+, HER2- early breast cancer.

Exner R, Bago-Horvath Z, Bartsch R, Mittlboeck M, Retèl VP, Fitzal F, Rudas M, Singer C, Pfeiler G, Gnant M, Jakesz R, Dubsky P.

Br J Cancer. 2014 Aug 26;111(5):837-42. doi: 10.1038/bjc.2014.339. Epub 2014 Jul 8.

26.

BRCA-1 methylation and TP53 mutation in triple-negative breast cancer patients without pathological complete response to taxane-based neoadjuvant chemotherapy.

Foedermayr M, Sebesta M, Rudas M, Berghoff AS, Promberger R, Preusser M, Dubsky P, Fitzal F, Gnant M, Steger GG, Weltermann A, Zielinski CC, Zach O, Bartsch R.

Cancer Chemother Pharmacol. 2014 Apr;73(4):771-8. doi: 10.1007/s00280-014-2404-1. Epub 2014 Feb 14.

PMID:
24526178
27.

Standardization of morbidity assessment in breast cancer surgery using the Clavien Dindo Classification.

Panhofer P, Ferenc V, Schütz M, Gleiss A, Dubsky P, Jakesz R, Gnant M, Fitzal F.

Int J Surg. 2014;12(4):334-9. doi: 10.1016/j.ijsu.2014.01.012. Epub 2014 Jan 31.

28.

Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24).

Steger GG, Greil R, Lang A, Rudas M, Fitzal F, Mlineritsch B, Hartmann BL, Bartsch R, Melbinger E, Hubalek M, Stoeger H, Dubsky P, Ressler S, Petzer AL, Singer CF, Muss C, Jakesz R, Gampenrieder SP, Zielinski CC, Fesl C, Gnant M; Austrian Breast and Colorectal Study Group (ABCSG).

Ann Oncol. 2014 Feb;25(2):366-71. doi: 10.1093/annonc/mdt508. Epub 2013 Dec 16.

PMID:
24347519
29.

Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone.

Gnant M, Filipits M, Greil R, Stoeger H, Rudas M, Bago-Horvath Z, Mlineritsch B, Kwasny W, Knauer M, Singer C, Jakesz R, Dubsky P, Fitzal F, Bartsch R, Steger G, Balic M, Ressler S, Cowens JW, Storhoff J, Ferree S, Schaper C, Liu S, Fesl C, Nielsen TO; Austrian Breast and Colorectal Cancer Study Group.

Ann Oncol. 2014 Feb;25(2):339-45. doi: 10.1093/annonc/mdt494. Epub 2013 Dec 16.

PMID:
24347518
30.

Impact of body mass index on estradiol depletion by aromatase inhibitors in postmenopausal women with early breast cancer.

Pfeiler G, Königsberg R, Hadji P, Fitzal F, Maroske M, Dressel-Ban G, Zellinger J, Exner R, Seifert M, Singer C, Gnant M, Dubsky P.

Br J Cancer. 2013 Sep 17;109(6):1522-7. doi: 10.1038/bjc.2013.499. Epub 2013 Sep 3.

31.

The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial.

Gnant M, Pfeiler G, Stöger H, Mlineritsch B, Fitzal F, Balic M, Kwasny W, Seifert M, Stierer M, Dubsky P, Greil R, Steger G, Samonigg H, Fesl C, Jakesz R.

Br J Cancer. 2013 Aug 6;109(3):589-96. doi: 10.1038/bjc.2013.367. Epub 2013 Jul 18.

32.

Efficacy of tamoxifen ± aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: an analysis of 1509 patients of the ABCSG-06 trial.

Pfeiler G, Stöger H, Dubsky P, Mlineritsch B, Singer C, Balic M, Fitzal F, Moik M, Kwasny W, Selim U, Renner K, Ploner F, Steger GG, Seifert M, Hofbauer F, Sandbichler P, Samonigg H, Jakesz R, Greil R, Fesl C, Gnant M; ABCSG.

Br J Cancer. 2013 Apr 16;108(7):1408-14. doi: 10.1038/bjc.2013.114. Epub 2013 Mar 19.

33.

German, Austrian and Swiss consensus conference on the diagnosis and local treatment of the axilla in breast cancer.

AGO; DGS; SGS; ÖGS; Panelists; Executive Board Members, Hoffmann J, Souchon R, Lebeau A, Öhlschlegel C, Gruber G, Rageth C, Weber W, Harbeck N, Janni W, Kreipe H, Fitzal F, Resch A, Bago-Horvath Z, Peintinger F.

Eur J Cancer. 2013 Jul;49(10):2277-83. doi: 10.1016/j.ejca.2013.01.034. Epub 2013 Mar 13.

PMID:
23490652
34.

Results of the First Austrian Multidisciplinary Expert Panel on Controversies in Local Treatment of Breast Cancer.

Knauer M, Gnant M, Fitzal F.

Breast Care (Basel). 2012 Feb;7(1):61-66. Epub 2012 Feb 20.

35.

Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer.

Bartsch R, Bago-Horvath Z, Berghoff A, DeVries C, Pluschnig U, Dubsky P, Rudas M, Mader RM, Rottenfusser A, Fitzal F, Gnant M, Zielinski CC, Steger GG.

Eur J Cancer. 2012 Sep;48(13):1932-8. doi: 10.1016/j.ejca.2012.03.002. Epub 2012 Mar 27.

PMID:
22459763
36.

Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group.

Dubsky PC, Jakesz R, Mlineritsch B, Pöstlberger S, Samonigg H, Kwasny W, Tausch C, Stöger H, Haider K, Fitzal F, Singer CF, Stierer M, Sevelda P, Luschin-Ebengreuth G, Taucher S, Rudas M, Bartsch R, Steger GG, Greil R, Filipcic L, Gnant M.

J Clin Oncol. 2012 Mar 1;30(7):722-8. doi: 10.1200/JCO.2011.36.8993. Epub 2012 Jan 23.

PMID:
22271481
37.

Brain metastases free survival differs between breast cancer subtypes.

Berghoff A, Bago-Horvath Z, De Vries C, Dubsky P, Pluschnig U, Rudas M, Rottenfusser A, Knauer M, Eiter H, Fitzal F, Dieckmann K, Mader RM, Gnant M, Zielinski CC, Steger GG, Preusser M, Bartsch R.

Br J Cancer. 2012 Jan 31;106(3):440-6. doi: 10.1038/bjc.2011.597. Epub 2012 Jan 10.

38.

Prognostic value of number of removed lymph nodes, number of involved lymph nodes, and lymph node ratio in 7502 breast cancer patients enrolled onto trials of the Austrian Breast and Colorectal Cancer Study Group (ABCSG).

Tausch C, Taucher S, Dubsky P, Seifert M, Reitsamer R, Kwasny W, Jakesz R, Fitzal F, Filipcic L, Fridrik M, Greil R, Gnant M.

Ann Surg Oncol. 2012 Jun;19(6):1808-17. doi: 10.1245/s10434-011-2189-y. Epub 2011 Dec 30.

PMID:
22207051
39.

Objectively measured breast symmetry has no influence on quality of life in breast cancer patients.

Exner R, Krois W, Mittlböck M, Dubsky P, Jakesz R, Gnant M, Fitzal F.

Eur J Surg Oncol. 2012 Feb;38(2):130-6. doi: 10.1016/j.ejso.2011.10.012. Epub 2011 Dec 5.

PMID:
22152943
40.

Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases.

Bartsch R, Berghoff A, Pluschnig U, Bago-Horvath Z, Dubsky P, Rottenfusser A, DeVries C, Rudas M, Fitzal F, Dieckmann K, Mader RM, Gnant M, Zielinski CC, Steger GG.

Br J Cancer. 2012 Jan 3;106(1):25-31. doi: 10.1038/bjc.2011.531. Epub 2011 Nov 29.

41.

A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors.

Filipits M, Rudas M, Jakesz R, Dubsky P, Fitzal F, Singer CF, Dietze O, Greil R, Jelen A, Sevelda P, Freibauer C, Müller V, Jänicke F, Schmidt M, Kölbl H, Rody A, Kaufmann M, Schroth W, Brauch H, Schwab M, Fritz P, Weber KE, Feder IS, Hennig G, Kronenwett R, Gehrmann M, Gnant M; EP Investigators.

Clin Cancer Res. 2011 Sep 15;17(18):6012-20. doi: 10.1158/1078-0432.CCR-11-0926. Epub 2011 Aug 1.

42.

Neoadjuvant chemotherapy increases the rate of breast conservation in lobular-type breast cancer patients.

Fitzal F, Mittlboeck M, Steger G, Bartsch R, Rudas M, Dubsky P, Riedl O, Jakesz R, Gnant M.

Ann Surg Oncol. 2012 Feb;19(2):519-26. doi: 10.1245/s10434-011-1879-9. Epub 2011 Jul 9.

PMID:
21743980
43.

Oncologic safety of breast conserving surgery after tumour downsizing by neoadjuvant therapy: a retrospective single centre cohort study.

Fitzal F, Riedl O, Mittlböck M, Dubsky P, Bartsch R, Steger G, Jakesz R, Gnant M.

Breast Cancer Res Treat. 2011 May;127(1):121-8. doi: 10.1007/s10549-010-1164-9. Epub 2010 Sep 17.

PMID:
20848185
44.

New Developments in Breast Cancer Therapy Presented at ASCO 2010.

Müllera V, Dubsky P, Fehm T, Fitzal F, Huober J, Schmidt M, Steger G.

Breast Care (Basel). 2010 Aug;5(4):266-271. Epub 2010 Aug 9. No abstract available.

45.

Oncoplastic surgery: "a rolling stone gathers no moss".

Fitzal F.

Breast. 2010 Dec;19(6):437-8. doi: 10.1016/j.breast.2010.03.027. Epub 2010 Apr 24. No abstract available.

PMID:
20421163
46.

Vienna international summer school on experimental and clinical oncology for medical students: an Austrian cancer education project.

Fromm-Haidenberger S, Pohl G, Widder J, Kren G, Fitzal F, Bartsch R, de Vries J, Zielinski C, Pötter R.

J Cancer Educ. 2010 Mar;25(1):51-4. doi: 10.1007/s13187-009-0011-3.

PMID:
20082180
47.

Adjuvant bisphosphonates in endocrine-responsive breast cancer: what is their place in therapy?

Gnant M, Blaha P, Dubsky P, Exner R, Fitzal F, Sporn E, Panhofer P, Borgo AD, Bigenzahn S, Steger G, Jakesz R.

Ther Adv Med Oncol. 2009 Nov;1(3):123-36. doi: 10.1177/1758834009344594.

48.

Breast cancer chemoprevention - a vision not yet realized.

Blaha P, Dubsky P, Fitzal F, Bachleitner-Hofmann T, Jakesz R, Gnant M, Steger G.

Eur J Cancer Care (Engl). 2009 Sep;18(5):438-46. doi: 10.1111/j.1365-2354.2008.00951.x. Epub 2009 Jul 20. Review.

PMID:
19686352
49.

A combined high temporal and high spatial resolution 3 Tesla MR imaging protocol for the assessment of breast lesions: initial results.

Pinker K, Grabner G, Bogner W, Gruber S, Szomolanyi P, Trattnig S, Heinz-Peer G, Weber M, Fitzal F, Pluschnig U, Rudas M, Helbich T.

Invest Radiol. 2009 Sep;44(9):553-8. doi: 10.1097/RLI.0b013e3181b4c127.

PMID:
19652611
50.

Maintaining bone density in patients undergoing treatment for breast cancer: is there an adjuvant benefit?

Gnant M, Dubsky P, Fitzal F, Blaha P, Schoppmann S, Steger G, Marth C, Samonigg H, Hüttner K, Fohler H, Ruecklinger E, Jakesz R, Greil R; Austrian Breast and Colorectal Cancer Study Group.

Clin Breast Cancer. 2009 Jun;9 Suppl 1:S18-27. doi: 10.3816/CBC.2009.s.002. Review.

PMID:
19561003

Supplemental Content

Loading ...
Support Center